Deucravacitinib

CHEMBL4435170 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

425.5 g/mol

LogP

1.2

Phase

4

A targeted oral medication that selectively inhibits TYK2, an enzyme involved in immune signaling pathways that drive inflammatory diseases. It is used to treat psoriasis and is being studied for other inflammatory conditions.

Peso molecular

425,5000 g/mol

LogP

1,20

TPSA

136,00 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Cáncer de próstata Dermatitis atópica Enfermedad inflamatoria intestinal Lupus eritematoso sistémico Psoriasis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC

InChI

InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3

Molecular Formula

C20H22N8O3

HBD / HBA

3 / 8

Enlaces Rotables

7

Átomos Pesados

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A targeted oral medication that selectively inhibits TYK2, an enzyme involved in immune signaling pathways that drive inflammatory diseases. It is used to treat psoriasis and is being studied for other inflammatory conditions.

Yes, Deucravacitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4435170. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 134821691. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Deucravacitinib en PillFYI

Estructura

Datos Rápidos

Fórmula: C20H22N8O3
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.